Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

2016241 citationsJournal Articlehybrid Open Access

Authors

Drug survival was superior for ustekinumab compared with infliximab, adalimumab and etanercept in patients with psoriasis.

Responsible consumption and production

Published in: Journal of the European Academy of Dermatology and Venereology

Volume 30, Issue 7, pp. 1148-1158

Field-Weighted Citation Impact: 17.57